GlaxoSmithKline (GSK) has acquired the Chinese pharmaceutical company Nanjing MeiRui Pharma for approximately US$70 M in cash, emphasising its focus on emerging markets. In another deal, Meda, a Swedish speciality pharmaceutical company, has purchased three well-established OTC products in the US from GSK for SEK235 M (US$34 M).